Combined treatment of congenital pseudarthrosis of the tibia, including recombinant human bone morphogenetic protein-2: a case series.

Alexander Simon Spiro; Kornelia Babin; S Lipovac; P Stenger; K Mladenov; Martin Rupprecht; Johannes Maria Rueger; Ralf Stücker

Combined treatment of congenital pseudarthrosis of the tibia, including recombinant human bone morphogenetic protein-2: a case series.

Standard

Combined treatment of congenital pseudarthrosis of the tibia, including recombinant human bone morphogenetic protein-2: a case series. / Spiro, Alexander Simon; Babin, Kornelia; Lipovac, S; Stenger, P; Mladenov, K; Rupprecht, Martin; Rueger, Johannes Maria; Stücker, Ralf.

In: J BONE JOINT SURG BR, Vol. 93, No. 5, 5, 2011, p. 695-699.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Spiro, AS, Babin, K, Lipovac, S, Stenger, P, Mladenov, K, Rupprecht, M, Rueger, JM & Stücker, R 2011, 'Combined treatment of congenital pseudarthrosis of the tibia, including recombinant human bone morphogenetic protein-2: a case series.', J BONE JOINT SURG BR, vol. 93, no. 5, 5, pp. 695-699. <http://www.ncbi.nlm.nih.gov/pubmed/21511938?dopt=Citation>

APA

Spiro, A. S., Babin, K., Lipovac, S., Stenger, P., Mladenov, K., Rupprecht, M., Rueger, J. M., & Stücker, R. (2011). Combined treatment of congenital pseudarthrosis of the tibia, including recombinant human bone morphogenetic protein-2: a case series. J BONE JOINT SURG BR, 93(5), 695-699. [5]. http://www.ncbi.nlm.nih.gov/pubmed/21511938?dopt=Citation

Vancouver

Spiro AS, Babin K, Lipovac S, Stenger P, Mladenov K, Rupprecht M et al. Combined treatment of congenital pseudarthrosis of the tibia, including recombinant human bone morphogenetic protein-2: a case series. J BONE JOINT SURG BR. 2011;93(5):695-699. 5.

Bibtex

@article{875997a6226547dba7f6565bec26146e,

title = "Combined treatment of congenital pseudarthrosis of the tibia, including recombinant human bone morphogenetic protein-2: a case series.",

abstract = "The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) for the treatment of congenital pseudarthrosis of the tibia has been investigated in only one previous study, with promising results. The aim of this study was to determine whether rhBMP-2 might improve the outcome of this disorder. We reviewed the medical records of five patients with a mean age of 7.4 years (2.3 to 21) with congenital pseudarthrosis of the tibia who had been treated with rhBMP-2 and intramedullary rodding. Ilizarov external fixation was also used in four of these patients. Radiological union of the pseudarthrosis was evident in all of them at a mean of 3.5 months (3.2 to 4) post-operatively. The Ilizarov device was removed after a mean of 4.2 months (3.0 to 5.3). These results indicate that treatment of congenital pseudarthrosis of the tibia using rhBMP-2 in combination with intramedullary stabilisation and Ilizarov external fixation may improve the initial rate of union and reduce the time to union. Further studies with more patients and longer follow-up are necessary to determine whether this surgial procedure may significantly enhance the outcome of congenital pseudarthrosis of the tibia, considering the refracture rate (two of five patients) in this small case series.",

keywords = "Humans, Male, Female, Young Adult, Treatment Outcome, Follow-Up Studies, Combined Modality Therapy, Child, Preschool, Retrospective Studies, Ankle Joint/physiopathology, Bone Morphogenetic Protein 2, Bone Morphogenetic Proteins/*therapeutic use, External Fixators, Fracture Fixation, Intramedullary/methods, Fracture Healing/drug effects, Ilizarov Technique, Knee Joint/physiopathology, Pseudarthrosis/congenital/drug therapy/radiography/surgery, Range of Motion, Articular, Recombinant Proteins/*therapeutic use, Tibial Fractures/*drug therapy/radiography/surgery, Transforming Growth Factor beta/*therapeutic use, Humans, Male, Female, Young Adult, Treatment Outcome, Follow-Up Studies, Combined Modality Therapy, Child, Preschool, Retrospective Studies, Ankle Joint/physiopathology, Bone Morphogenetic Protein 2, Bone Morphogenetic Proteins/*therapeutic use, External Fixators, Fracture Fixation, Intramedullary/methods, Fracture Healing/drug effects, Ilizarov Technique, Knee Joint/physiopathology, Pseudarthrosis/congenital/drug therapy/radiography/surgery, Range of Motion, Articular, Recombinant Proteins/*therapeutic use, Tibial Fractures/*drug therapy/radiography/surgery, Transforming Growth Factor beta/*therapeutic use",

author = "Spiro, {Alexander Simon} and Kornelia Babin and S Lipovac and P Stenger and K Mladenov and Martin Rupprecht and Rueger, {Johannes Maria} and Ralf St{\"u}cker",

year = "2011",

language = "English",

volume = "93",

pages = "695--699",

number = "5",

}

RIS

TY - JOUR

T1 - Combined treatment of congenital pseudarthrosis of the tibia, including recombinant human bone morphogenetic protein-2: a case series.

AU - Spiro, Alexander Simon

AU - Babin, Kornelia

AU - Lipovac, S

AU - Stenger, P

AU - Mladenov, K

AU - Rupprecht, Martin

AU - Rueger, Johannes Maria

AU - Stücker, Ralf

PY - 2011

Y1 - 2011

N2 - The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) for the treatment of congenital pseudarthrosis of the tibia has been investigated in only one previous study, with promising results. The aim of this study was to determine whether rhBMP-2 might improve the outcome of this disorder. We reviewed the medical records of five patients with a mean age of 7.4 years (2.3 to 21) with congenital pseudarthrosis of the tibia who had been treated with rhBMP-2 and intramedullary rodding. Ilizarov external fixation was also used in four of these patients. Radiological union of the pseudarthrosis was evident in all of them at a mean of 3.5 months (3.2 to 4) post-operatively. The Ilizarov device was removed after a mean of 4.2 months (3.0 to 5.3). These results indicate that treatment of congenital pseudarthrosis of the tibia using rhBMP-2 in combination with intramedullary stabilisation and Ilizarov external fixation may improve the initial rate of union and reduce the time to union. Further studies with more patients and longer follow-up are necessary to determine whether this surgial procedure may significantly enhance the outcome of congenital pseudarthrosis of the tibia, considering the refracture rate (two of five patients) in this small case series.

AB - The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) for the treatment of congenital pseudarthrosis of the tibia has been investigated in only one previous study, with promising results. The aim of this study was to determine whether rhBMP-2 might improve the outcome of this disorder. We reviewed the medical records of five patients with a mean age of 7.4 years (2.3 to 21) with congenital pseudarthrosis of the tibia who had been treated with rhBMP-2 and intramedullary rodding. Ilizarov external fixation was also used in four of these patients. Radiological union of the pseudarthrosis was evident in all of them at a mean of 3.5 months (3.2 to 4) post-operatively. The Ilizarov device was removed after a mean of 4.2 months (3.0 to 5.3). These results indicate that treatment of congenital pseudarthrosis of the tibia using rhBMP-2 in combination with intramedullary stabilisation and Ilizarov external fixation may improve the initial rate of union and reduce the time to union. Further studies with more patients and longer follow-up are necessary to determine whether this surgial procedure may significantly enhance the outcome of congenital pseudarthrosis of the tibia, considering the refracture rate (two of five patients) in this small case series.

KW - Humans

KW - Male

KW - Female

KW - Young Adult

KW - Treatment Outcome

KW - Follow-Up Studies

KW - Combined Modality Therapy

KW - Child, Preschool

KW - Retrospective Studies

KW - Ankle Joint/physiopathology

KW - Bone Morphogenetic Protein 2

KW - Bone Morphogenetic Proteins/therapeutic use

KW - External Fixators

KW - Fracture Fixation, Intramedullary/methods

KW - Fracture Healing/drug effects

KW - Ilizarov Technique

KW - Knee Joint/physiopathology

KW - Pseudarthrosis/congenital/drug therapy/radiography/surgery

KW - Range of Motion, Articular

KW - Recombinant Proteins/therapeutic use

KW - Tibial Fractures/drug therapy/radiography/surgery

KW - Transforming Growth Factor beta/therapeutic use